No measurable benefit from supplements in the VITAL trial

Two sets of results from a major trial focused on the use of supplements to prevent cancer and heart disease are published today in the New England Journal of Medicine. … READ MORE …

Is Problem X really a side effect of ADT, or not …?

We have long been bedeviled by questions about some of the short- and the long-term side effects and complications of androgen deprivation therapy (ADT) in the treatment of prostate cancer. … READ MORE …

ADT and risk for cardiovascular complications of therapy

Not so long ago, we addressed the question of whether first-line androgen deprivation therapy (ADT) was really an appropriate form of care for any man with localized prostate cancer. … READ MORE …

Lowering risk of death from prostate cancer AND cardiovascular disease

Based on a specific case study, a new paper in Circulation by a group of clinicians at Vanderbilt University Medical Center describes their program designed to reduce risk of death from cardiovascular disease for prostate cancer patients on androgen deprivation therapy (ADT). … READ MORE …

Adding ADT to radiation therapy problematic for high-risk patients with history of heart disease

A new research letter just published in the Journal of the American Medical Association appears to confirm the risks associated with use of androgen deprivation therapy (ADT) for treatment of prostate cancer among men with a history of significant heart disease. … READ MORE …

Heart-related mortality in men on ADT: a current perspective

A newly published study in BJU International suggests (unsurprisingly) that androgen deprivation therapy (ADT) is associated with an increased risk of death among men with such cardiovascular conditions as congestive heart failure or prior heart attacks. … READ MORE …